We used Roscovitine, an ATP‐competitive inhibitor that has preferential activity against CDK5, but also blocks CDK1, 2, 7, and 9 (Meijer et al, 1997; Cicenas et al, 2015), and performed drug synergy assays in AML cell lines. The gene discussed is CDK5; the disease is acute myeloid leukemia.